Peroxiredoxin I and II as novel therapeutic molecular targets in cervical cancer treatment through regulation of endoplasmic reticulum stress induced by bleomycin

Hu-Nan Sun,Da-Yu Ma,Xiao-Yu Guo,Ying-Ying Hao,Mei-Hua Jin,Ying-Hao Han,Xun Jin,Taeho Kwon

DOI: https://doi.org/10.1038/s41420-024-02039-7

2024-06-01

Cell Death Discovery

Abstract:Cervical cancer, significantly affecting women worldwide, often involves treatment with bleomycin, an anticancer agent targeting breast, ovarian, and cervical cancers by generating reactive oxygen species (ROS) to induce cancer cell death. The Peroxiredoxin (PRDX) family, particularly PRDX1 and 2, plays a vital role in maintaining cellular balance by scavenging ROS, thus mitigating the damaging effects of bleomycin-induced mitochondrial and cellular oxidative stress. This process reduces endoplasmic reticulum (ER) stress and prevents cell apoptosis. However, reducing PRDX1 and 2 levels reverses their protective effect, increasing apoptosis. This research highlights the importance of PRDX1 and 2 in cervical cancer treatments with bleomycin, showing their potential to enhance treatment efficacy by managing ROS and ER stress and suggesting a therapeutic strategy for improving outcomes in cervical cancer treatment.

cell biology

What problem does this paper attempt to address?

The paper aims to explore the roles of peroxiredoxins I and II (PRDX1 and PRDX2) in the treatment of cervical cancer and to enhance the efficacy of bleomycin (BLM) by modulating endoplasmic reticulum stress. Specifically, the study found:

1. **Mechanism of Action of Bleomycin**: Bleomycin can induce apoptosis in cervical cancer cells by generating reactive oxygen species (ROS). This drug disrupts mitochondrial membrane potential and increases ROS levels, leading to endoplasmic reticulum stress and cell apoptosis.

2. **Roles of PRDX1 and PRDX2**: As antioxidant enzymes, PRDX1 and PRDX2 can eliminate ROS and alleviate cell damage caused by bleomycin. Experimental results show that overexpression of PRDX1 and PRDX2 can reduce bleomycin-induced endoplasmic reticulum stress and cell apoptosis, while knocking down these proteins exacerbates endoplasmic reticulum stress and cell apoptosis.

3. **Clinical Relevance**: The study also found that high expression of PRDX1 and PRDX2 in cervical cancer patients is associated with lower survival rates, suggesting that these proteins may be potential therapeutic targets.

4. **Validation in Animal Experiments**: In a mouse xenograft model, the combined use of bleomycin and Conodin A significantly inhibited tumor growth, indicating that this combination therapy has a stronger anti-tumor effect.

In summary, this paper reveals the importance of PRDX1 and PRDX2 in the treatment of cervical cancer and proposes a new strategy to enhance the efficacy of bleomycin by modulating these proteins.